SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Hyperpolarized ^{13}C magnetic resonance spectroscopy (MRS) to predict tumors that will respond to anti-VEGF therapy	Mouse studies suggest hyperpolarized ^{13}C MRS could help detect early tumor response to anti-VEGF therapy. In mice with colorectal cancer xenografts, MRS using ^{13}C pyruvate and ^{13}C fumarate probes detected less metabolic label flux in tumors responding to Avastin than in nonresponding tumors. Clinical trials of the technology in undisclosed indications are ongoing. Chugai Pharmaceutical Co. Ltd. and the Genentech Inc. unit of Roche market Avastin bevacizumab to treat various cancers.	Technology patented by GE Healthcare and the University of Cambridge; licensing status undisclosed	Bohndiek, S.E. *et al. Cancer Res.*; published online Jan. 5, 2012; doi:10.1158/0008-5472.CAN-11-2795 **Contact:** Kevin M. Brindle, University of Cambridge, Cambridge, U.K. e-mail: kmb@mole.bio.cam.ac.uk

SciBX 5(4); doi:10.1038/scibx.2012.113
Published online Jan. 26, 2012